DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice

Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 306

This Paper With 12 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_NAMJ-4-2_002

تاریخ نمایه سازی: 18 تیر 1398

Abstract:

Objective(s): Leishmaniasis is a complex parasitic disease that represents a major public health problem. Despite numerous attempts over the past decades, yet there is no effective vaccine against human leishmaniasis probably due to the lack of suitable adjuvants. In this study, a first generation liposomal-based Leishmania vaccine was developed using soluble Leishmania major antigens (SLA) and á, Ü-trehalose6, 6 - dibehenat (TDB) as an immunostimulatory adjuvant. In this liposome structure, the cationic lipid Dimethyldioctadecylammonium (DDA) provides intrinsic adjuvant activity and cholesterol was added as a membrane stabilizer. Liposomes containing SLA were prepared. Materials and Methods: BALB/c mice were subcutaneously (sc) immunized with Lip (DDA/TDB/CHOL)-SLA+, Lip (DDA/TDB)-SLA+, Lip (DDA)-SLA+, Lip (DDA/CHOL)-SLA+, SLA or Tris-HCl buffer. Immunization was done every two weeks for three weeks. The immunized mice were then challenged sc in the left footpad with 1×106 stationary phase L. major promastigotes (50 ìl), at 2 weeks after last booster injection.Results: mice immunized with any of the liposomal formulations containing SLA (Lip-SLA+), substantially increased footpad swelling and parasite loads of foot and spleen with no significant difference compared to Tris-HCl buffer or SLA alone. Lip-SLA+ formulations induced a mixed Th1/Th2 immune response characterized by IFN-ã and IL-4 production as well as high levels of IgG1 anti-Leishmania antibody. Conclusion: immunization with liposomes containing DDA and/or TDB in combination with SLA induces a mixed Th1/Th2 immune response and is not an appropriate strategy for preferential induction of a Th1 response and protection against leishmaniasis.

Authors

Mansure Hojatizade

Pathobiology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran|Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran

Ali Badiee

Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Ali Khamesipour

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Abbas Mirshafiey

Pathobiology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Dumonteil E, Jesus R-SM, Javier E-O, del Rosario Ga-MM. DNA ...
  • Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, ...
  • Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, ...
  • Kongkaew W, Siriarayaporn P, Leelayoova S, Supparatpinyo K, Areechokchai D, ...
  • Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. ...
  • Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, ...
  • Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, ...
  • Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, ...
  • Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. ...
  • Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, ...
  • Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, ...
  • Valian HK, Kenedy LKA, Rostami MN, Mohammadi AM, Khamesipour A. ...
  • Marques-da-Silva EA, Coelho EA, Gomes DC, Vilela MC, Masioli CZ, ...
  • Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol. ...
  • Badiee A, Shargh VH, Khamesipour A, Jaafari MR. Micro/nanoparticle adjuvants ...
  • O’Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants ...
  • Henriksen-Lacey M, Bramwell VW, Christensen D, Agger E-M, Andersen P, ...
  • Hilgers LT, Snippe H. DDA as an immunological adjuvant. Res. ...
  • Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of ...
  • Vangala A, Bramwell VW, McNeil S, Christensen D, Agger EM, ...
  • Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, ...
  • Kirby DJ, Kaur R, Agger EM, Andersen P, Bramwell VW, ...
  • Moghaddam B, Ali MH, Wilkhu J, Kirby DJ, Mohammed AR, ...
  • Xu L, Anchordoquy TJ. Cholesterol domains in cationic lipid/DNA complexes ...
  • Bakouche O, Gerlier D. Enhancement of immunogenicity of tumour virus ...
  • Sharifi I, Fekri AR, Aflatonian M-R, Khamesipour A, Nadim A, ...
  • Javadian E, Nadim A, Tahvildare-Bidruni G, Assefi V. Epidemiology of ...
  • Scott P, Pearce E, Natovitz P, Sher A. Vaccination against ...
  • Feitosa E, Barreleiro P, Olofsson G. Phase transition in dioctadecyldimethylammonium ...
  • Jaafari MR, Ghafarian A, Farrokh-Gisour A, Samiei A, Kheiri MT, ...
  • Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Ranjbar R, ...
  • Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Tafaghodi M, ...
  • Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Tafaghodi M, ...
  • Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, ...
  • Badiee A, Jaafari MR, Khamesipour A. Leishmania major: immune response ...
  • Huang Z, Jaafari MR, Szoka FC. Disterolphospholipids: nonexchangeable lipids and ...
  • Modabber F. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 1995;89:83-88. ...
  • Yan W, Chen W, Huang L. Mechanism of adjuvant activity ...
  • Kaur R, Henriksen-Lacey M, Wilkhu J, Devitt A, Christensen D, ...
  • Firouzmand H, Badiee A, Khamesipour A, Heravi Shargh V, Alavizadeh ...
  • Brgles M, Habjanec L, Halassy B, Tomašiæ J. Liposome fusogenicity ...
  • Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, ...
  • Bhowmick S, Ali N. Recent developments in leishmaniasis vaccine delivery ...
  • Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, ...
  • Shargh VH, Jaafari MR, Khamesipour A, Jaafari I, Jalali SA, ...
  • Hafez I, Maurer N, Cullis P. On the mechanism whereby ...
  • Ignatius R, Mahnke K, Rivera M, Hong K, Isdell F, ...
  • Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J. Glob ...
  • Watson DS, Endsley AN, Huang L. Design considerations for liposomal ...
  • McLennan DN, Porter CJ, Charman SA. Subcutaneous drug delivery and ...
  • Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. ...
  • Badiee A, Khamesipour A, Samiei A, Soroush D, Shargh VH, ...
  • Bhowmick S, Ravindran R, Ali N. Leishmanial antigens in liposomes ...
  • Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, ...
  • Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo Jr ...
  • Lonez C, Vandenbranden M, Ruysschaert J-M. Cationic liposomal lipids: from ...
  • نمایش کامل مراجع